Plain-English translation of NCT05674305 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether patients with nasopharyngeal cancer who show a strong early response to chemotherapy (specifically, when a virus marker in their blood disappears after the first round of treatment) can skip the additional chemotherapy that normally goes along with radiation. Instead of receiving radiation plus chemotherapy together, some patients would receive radiation alone. The goal is to see if this simpler approach works just as well while potentially reducing side effects.
Standard treatment for advanced nasopharyngeal cancer combines radiation with chemotherapy, but this combination can cause difficult side effects. Doctors have noticed that patients whose bodies respond very well to an initial round of chemotherapy (shown by the disappearance of a virus marker in their blood) may not need the added chemotherapy during radiation, and this trial will test whether that's true.
You likely qualify if…
You likely don't qualify if…
After you complete three cycles of initial chemotherapy and your virus marker has disappeared, you will be randomly assigned to one of two groups. One group will receive radiation therapy alone to the head and neck region. The other group will receive the same radiation therapy plus two additional cycles of chemotherapy given at the same time. The trial will follow your health and cancer response to see which approach works better and causes fewer side effects.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China